Franck S Rousseau

Summary

Affiliation: Gilead Sciences
Country: USA

Publications

  1. ncbi request reprint Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients
    Franck S Rousseau
    Triangle Pharmaceuticals, Durham, North Carolina 27717, USA
    J Infect Dis 188:1652-8. 2003
  2. ncbi request reprint Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection
    Laurene H Wang
    Gilead Sciences, Inc, Durham, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 20:1173-82. 2004
  3. ncbi request reprint Reproductive toxicology profile of emtricitabine in mice and rabbits
    George M Szczech
    Triangle Pharmaceuticals, Inc, 4611 University Drive, PO Box 50530, Durham, NC 27717, USA
    Reprod Toxicol 17:95-108. 2003
  4. ncbi request reprint Intracellular pharmacology of emtricitabine and tenofovir
    Robert C Stevens
    Clin Infect Dis 39:877-8; author reply 878-9. 2004
  5. ncbi request reprint Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, Georgia, USA
    AIDS 19:1607-15. 2005

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients
    Franck S Rousseau
    Triangle Pharmaceuticals, Durham, North Carolina 27717, USA
    J Infect Dis 188:1652-8. 2003
    ..The long plasma half-life and the superior antiviral activity versus 3TC of the 200 mg/day FTC dose confirmed the results of other studies and led to the selection of this dose for subsequent therapeutic trials...
  2. ncbi request reprint Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection
    Laurene H Wang
    Gilead Sciences, Inc, Durham, North Carolina 27709, USA
    AIDS Res Hum Retroviruses 20:1173-82. 2004
    ..HIV RNA suppression (PD) correlates well with PBMC FTC-5'-TP levels (PK), both reaching a plateau at doses > or = 200 mg/day. The PK and PD characteristics of FTC demonstrate that it is a once daily nucleoside RT inhibitor...
  3. ncbi request reprint Reproductive toxicology profile of emtricitabine in mice and rabbits
    George M Szczech
    Triangle Pharmaceuticals, Inc, 4611 University Drive, PO Box 50530, Durham, NC 27717, USA
    Reprod Toxicol 17:95-108. 2003
    ..The development and fertility of F(1) progeny were unaffected by emtricitabine in a mouse pre- and post-natal study. These data demonstrate a favorable pre-clinical reproductive safety profile for emtricitabine...
  4. ncbi request reprint Intracellular pharmacology of emtricitabine and tenofovir
    Robert C Stevens
    Clin Infect Dis 39:877-8; author reply 878-9. 2004
  5. ncbi request reprint Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, Georgia, USA
    AIDS 19:1607-15. 2005
    ..To evaluate the pharmacodynamics and safety of escalating doses of amdoxovir (DAPD) monotherapy administered to treatment-naive and experienced HIV-1-infected patients over 15 days...